AbCheck

About:

AbCheck provides an antibody discovery platform that discovers and optimizes human therapeutic antibodies.

Website: https://abcheckantibodies.com/

Description:

AbCheck provides an antibody discovery platform that discovers and optimizes human therapeutic antibodies. The company provides drug candidates through discovery collaborations or strategic research partnerships based on flexible business terms including royalty-free agreements. It generates target-specific human antibody domains which can be used in distinct therapeutic formats. AbCheck was founded in 2009 and is a spin-out of Affimed’s technology discovery platform. It is a wholly owned subsidiary of Affimed GmbH, a biopharmaceutical company developing highly targeted cancer immunotherapies.

Total Funding Amount:

1M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Plzen, Plzensky kraj, Czech Republic

Founded Date:

2009-01-01

Contact Email:

info(AT)abcheckantibodies.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2023-03-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai